Revive Therapeutics : RVV Investor Fact Sheet H1 2023

Corporate Fact Sheet 1H-2023

OVERVIEW

• Focus on repurposing drugs for rare & infectious diseases
• Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (FDA Phase 3)
• Developing Psilocybin and Cannabidiol therapeutics for various CNS and inflammatory disorders
• Robust patent portfolio(15 patents and patent applications)

• Awarded FDA Orphan Drug Status for CBD in the treatment of Autoimmune Hepatitis
• Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)
• Significantly undervalued compared to its peers

PRODUCT PIPELINE

EXPECTED MILESTONES 1H-2023

FDA approval of protocol change for COVID-19 Phase 3 study primary endpoint

Schedule of DSMB meeting for COVID-19 Phase 3 study primary endpoint

Phase 2 study - Psilocybin in Methamphetamine Disorder at University of Wisconsin

Manufacturing scale-up of Psilocybin oral thin film strip for FDA IND

STRATEGIC PARTNERS

TEAM

Management

Michael Frank, Chairman & CEO

Carmelo Marrelli, CFO

Derrick Welch, COO, Psilocin Pharma

Scientific and Clinical

Dr. Kelly McKee, CSO Dr. Arshi Kizilbash, M.D.

Dr. Osnesmo Mpanju, Regulatory Affairs

Dr. John Fahy, MD, Clinical and Scientific Advisor

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

VALUATION COMPARISON			STOCK INFORMATION
			Ticker:	CSE: RVV, OTCQB: RVVTF,
			FRANKFURT: 31R
			Share Price:	$0.13(Feb 2, 2023)
			52-week High / Low:	CAD $0.49 / $0.10
			Shares Outstanding:	353,804,341
			Market Cap:	CAD ~ 45,000,000

Revive Therapeutics Ltd. | 82 Richmond Street East, Toronto, ON M5C 1P1 | 1-888-901-0036 | [e-mail]| revivethera.com